StemCells, Inc. , a leading stem cell company developing novel cell-based therapeutics for treating diseases of the central nervous system with high unmet medical need, announced today that it has completed transplanting the six patients comprising the first cohort of its Phase II Pathway Study. The first cohort is an open-label dose escalation arm to determine the cell dose to be used for the second cohort of the study.
http://ift.tt/1FOeCnO
http://ift.tt/1FOeCnO
No comments:
Post a Comment